Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

This study has been completed.
Ariad Pharmaceuticals
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: May 4, 2005
Last updated: November 18, 2015
Last verified: November 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2007
  Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):